Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient

BACKGROUND: The compound letermovir (LMV) has recently been approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant. LMV inhibits CMV replication by binding to the viral terminase complex. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Susanne, Michel, Manuela, Stamminger, Thomas, Michel, Detlef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505103/
https://www.ncbi.nlm.nih.gov/pubmed/31068147
http://dx.doi.org/10.1186/s12879-019-4016-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505103/
https://www.ncbi.nlm.nih.gov/pubmed/31068147
http://dx.doi.org/10.1186/s12879-019-4016-1

Ejemplares similares